Log In
Monday 24th June 2019

Boob job jab withdrawn

23rd April 2012

The British Association of Aesthetic Plastic Surgeons have given their support to a decision to withdraw an injectable filler used to enhance breasts.


A survey carried out by BAAPS found that a quarter of doctors who gave Macrolane injections said their patients reported complications.

The filler, also known as the "lunchtime boob jab", is manufactured by Q-Med. The Medicines and Healthcare Regulatory Agency said it could affect mammogram readings. 

A spokesman for Q-Med said all types of breast enhancement procedure could interfere with breast cancer screenings.

He added: "At present, there is a lack of consensus amongst radiologists regarding radiology examination of breasts treated with Macrolane."

In 2009 over 1,000 women in the UK were injected with the filler, according to BAAPS. 

BAAPS president Fazel Fatah said: "Any treatment can only be considered safe once it is known what long-term effect it has on cancer screening as this can affect such a high proportion of women."

"We have urged caution in the past against the use of fillers in the breast, especially when there is a lack of peer-reviewed results from controlled clinical trials."

He added that BAAPS had raised worries in the past about Macrolane causing lumps and capsular contracture after the use of the filler.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based applications for healthcare
© Mayden Foundation 2019